ASCO 2022 Conference Coverage


 

ASCO 2022 on Phase I/II Trial of Encorafenib, Cetuximab, & Nivolumab in Patients With MSS BRAFV600E mCRC

342 views
June 28, 2022
Comments 0
Login to view comments. Click here to Login